← Back to Search

Other

PRP vs Corticosteroids for Knee Osteoarthritis

Phase 1 & 2
Recruiting
Research Sponsored by University of Missouri-Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial compares two types of injections to treat knee osteoarthritis. It aims to see how each affects pain, function, and joint health. The study focuses on adults with knee osteoarthritis to find better long-term treatment options. One type of injection aims to address the underlying causes of osteoarthritis and has the potential to improve both symptoms and joint structure.

Who is the study for?
This trial is for people over 40 with moderate to severe knee osteoarthritis, but not at the end-stage. They must have a specific level of joint damage (KL grade 2-3) and be able to receive corticosteroid or biological treatments. Pregnant individuals, those with previous knee surgery, allergies to injections, or currently in another trial cannot participate.
What is being tested?
The study compares the effects of two types of knee injections: platelet-rich plasma and corticosteroid (Triamcinolone Acetonide). It measures their impact on pain, function, and joint cartilage changes through surveys and analysis of blood, urine, and synovial fluid samples from participants.
What are the potential side effects?
Potential side effects may include injection site reactions like pain or swelling. Corticosteroids can sometimes cause increased appetite, mood changes or raise blood sugar levels. Platelet-rich plasma's side effects are typically mild but could include tissue damage if improperly administered.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
The change From Baseline in Pain Scores on the Knee Injury and Osteoarthritis Outcome Score-Joint Replacement at 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months, and 12 months
The change From Baseline in Pain Scores on the Visual Analog Scale at 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months, and 12 months
The change From Baseline in Scores on the UCLA Activity Score at 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months, and 12 months

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Platelet-rich PlasmaExperimental Treatment1 Intervention
An injection at the initial visit of approximately 4-6 mL of PRP
Group II: SteroidActive Control1 Intervention
A 6mL injection at the initial visit of triamcinolone 40 mg/1 mL (Kenalog) with 5 mL of 1% lidocaine

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Corticosteroids reduce inflammation by inhibiting inflammatory pathways and decreasing the production of inflammatory mediators, providing short-term pain relief and improved joint function. Platelet-rich plasma (PRP) promotes tissue regeneration and healing by delivering a high concentration of growth factors to the affected area, enhancing cartilage repair and reducing inflammation. Understanding these mechanisms helps osteoarthritis patients and their healthcare providers choose the most appropriate treatment based on individual symptoms and treatment goals.
Osteoarthritis of the knee - biochemical aspect of applied therapies: a review.Pathophysiology and first-line treatment of osteoarthritis.

Find a Location

Who is running the clinical trial?

University of Missouri-ColumbiaLead Sponsor
379 Previous Clinical Trials
628,512 Total Patients Enrolled
12 Trials studying Osteoarthritis
12,760 Patients Enrolled for Osteoarthritis
Vicki Jones, MEd, CCRPStudy DirectorUniversity of Missouri-Columbia
Stacee Baker, MEd, RNStudy DirectorUniversity of Missouri-Columbia

Media Library

Platelet-rich plasma Inj (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05657496 — Phase 1 & 2
Osteoarthritis Research Study Groups: Steroid, Platelet-rich Plasma
Osteoarthritis Clinical Trial 2023: Platelet-rich plasma Inj Highlights & Side Effects. Trial Name: NCT05657496 — Phase 1 & 2
Platelet-rich plasma Inj (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05657496 — Phase 1 & 2
~24 spots leftby Dec 2025